2.0考虑所有的entity，比如user，project，采用collection entity来表示：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| name | string | 否 | 真实名字，不能为空 |
| nick | string | 否 | 显示名字 |
| addr | address |
否 | 地址 |
| contact | contact |
否 | 联系方式 |
| logo | URL | 是 | logo |
| abs | string | 否 | 一句话介绍，不能为空 |
| type | int32 | 否 | 类型，见下文 |
| tag | list(string) | 否 | 公共标签 |
| intro | string | 否 | 详细介绍 |
| onepage | object | 否 | 一页纸内容 |
| srcId | objectId | 否 | 如果不空，则表示这个数据是fork来的，默认000000000000000000000000 |
| ref | string | 否 | 外部唯一引用 |
| _deleted | bool | 否 | 是否待删除，只读 |
| _created | datetime | 否 | 创建时间，只读 |
| _updated | datetime | 否 | 最近更新时间，只读 |
| entr | entrepreneur |
是 | entrepreneur特有字段 |
| asset | asset |
是 | asset特有字段 |
其中type指向entity具体指向的类型，基于数值
| 值 | 意义 | 说明 |
|---|---|---|
| 2 | entrepreneur | 公司，可作为投资标的 |
| 8 | asset | 可被出售的产品，服务，技术等 |
srcId不为空的时候，表示该数据是fork来自srcId指向的数据。这样可以解决这样的问题：项目经理需要开始跟进一个项目的时候，他可以fork这个项目，这样项目经理在这个项目上的任何input都是归属于这个项目经理。
用于一页纸的介绍：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| banner | URL | 否 | bp的链接 |
| bg | string | 否 | 市场/背景 |
| high | string | 否 | 投资亮点 |
| prod | string | 否 | 产品/技术 |
| team | string | 否 | 团队亮点 |
可被投资的公司，即type == 2：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| bp | URL | 否 | bp的链接 |
| demand | demand |
否 | 融资需求 |
| fin | string | 否 | 财务亮点 |
| market | string | 否 | 市场背景 |
| tech | string | 否 | 技术亮点 |
| grant | string | 否 | 所获荣誉 |
机构或者用户提供的服务，产品，专利，临床实验等等，比如一个医疗器械，即type == 8：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| price | object | 否 | 价格 |
| price.cost | currency |
否 | 成本价 |
| price.eow | currency |
否 | 出厂价 |
| price.market | currency |
否 | 售价 |
| market | string | 否 | 市场背景 |
| tech | string | 否 | 技术亮点 |
| lic | list(string) | 否 | 批准/许可证 |
| stat | enumerate | 否 | 当前状态 |
| type | enumerate | 否 | 类型 |
status 是产品当前的状态：
| status | 说明 |
|---|---|
| 0 | 研发中 |
| 1 | 测试中 |
| 2 | 销售中 |
| 3 | 取消/终止 |
type 是产品当前的状态：
| type | 说明 |
|---|---|
| 0 | 产品 |
| 1 | 专利 |
| 2 | 临床实验 |
| 3 | 技术 |
demand表示一个融资需求/结果：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| demand.stage | enumerate | 否 | 当前阶段 |
| demand.amount | currency |
否 | 融资需求 |
| demand.val | currency |
否 | 对应投前估值 |
| demand.share | float | 否 | 对应估值出让百分比 |
| demand.due | datetime | 否 | 融资截止时间 |
金额：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| amount | float | 否 | 数额 |
| unit | string | 否 | 货币类型，比如USD，不能为空 |
地址字段：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| line1 | string | 否 | 地址第一行，通常是街道 |
| line2 | string | 否 | 地址第二行，通常是门牌 |
| city | string | 否 | 市，不能为空 |
| state | string | 否 | 省/州 |
| country | string | 否 | 国家，不能为空 |
| zip | string | 否 | 邮编 |
联系方式：
| 字段 | 类型 | 可选 | 说明 |
|---|---|---|---|
| website | URL | 否 | 网站 |
| 否 | 邮箱 | ||
| phone | string | 否 | 电话 |
| meet | string | 否 | Zoom的会议id，只读 |
注意_开始的字段表示系统生成的只读字段。
{
"_perm": [],
"_etag": "f76b6db901e1c02d36a5d1a592b044cb3ddf91dd",
"_id": "5c6faa2a0f69d50010c5df91",
"nick": "",
"type": 8,
"intro": "",
"_auth": {
"mac": "",
"wechat": "",
"linkedin": "",
"pwd": ""
},
"_created": "Fri, 06 May 2016 15:22:46 GMT",
"ref": "https://pharmalicensing.com/app/opportunity/detail/Anti-Human_s_Tenascin_s_Monoclonal_s_Antibodies_s_300-1,_s_300-2,_s_302-1_s_and_s_302-9/56659",
"_updated": "Thu, 04 Sep 2014 00:00:00 GMT",
"_links": {
"self": {
"title": "Asset",
"href": "asset/5c6faa2a0f69d50010c5df91"
}
},
"asset": {
"lic": [],
"price": {
"eow": {
"amount": 0,
"unit": "USD"
},
"market": {
"amount": 0,
"unit": "USD"
},
"cost": {
"amount": 0,
"unit": "USD"
}
},
"type": 3,
"tech": "# description\n\n\n\n# advantages\n\n\n\n",
"market": "# body\n\n\n\n# clinical_trials\n\n\n\n",
"stat": 0
},
"addr": {
"country": "United States",
"city": "Unknown",
"zip": "",
"line1": "",
"state": "",
"line2": ""
},
"abs": "MAbs 300-1, 300-3, 300-2, 302-1, 302-9 were derived by immunizing BALB/c mice with a high molecular weight fraction of culture supernatants of melanoma cells. Fusion was done with a non-secreting",
"srcId": "000000000000000000000000",
"pref": [],
"name": "Anti-Human Tenascin Monoclonal Antibodies 300-1, 300-2, 302-1 and 302-9",
"onepage": {
"bg": "",
"team": "",
"prod": "",
"high": ""
},
"contact": {
"email": "",
"website": "",
"phone": "",
"meet": ""
},
"tag": [
"Oncology",
"Screening",
"Genomics",
"Inflammation",
"Wound Healing",
"Proteomics",
"Clinical Trials",
"Platform",
"Immunology",
"Infectious Disease",
"Drug Discovery"
],
"logo": "https://buttondata.oss-cn-shanghai.aliyuncs.com/user.png",
"_deleted": false
}
{
"_perm": [],
"_etag": "be33e588f7cea15a809250ffe781bc381184b9dc",
"_id": "5c6ad7230f69d500100a6a95",
"nick": "",
"intro": "# Summary\n\nS005\n\n# Supplement Reason\n\nProcess Change - Manufacturer/Sterilizer/Packager/Supplier\n\n# Statement\n\nCHANGE IN THE BIOLOGICAL INDICATOR USED FOR THE STERILIZATION PROCESS.\n\n",
"type": 8,
"_auth": {
"mac": "",
"wechat": "",
"linkedin": "",
"pwd": ""
},
"_created": "Wed, 16 Dec 2009 00:00:00 GMT",
"ref": "P050046",
"_deleted": false,
"_links": {
"self": {
"title": "Asset",
"href": "asset/5c6ad7230f69d500100a6a95"
}
},
"_updated": "Tue, 12 Jan 2010 00:00:00 GMT",
"addr": {
"country": "",
"city": "ST. PAUL",
"zip": "",
"state": "MN",
"line1": "",
"line2": ""
},
"abs": "Permanent defibrillator electrodes",
"srcId": "000000000000000000000000",
"pref": [],
"name": "ACUITY STEERABLE",
"onepage": {
"bg": "",
"team": "",
"prod": "",
"high": ""
},
"contact": {
"meet": "",
"phone": "",
"website": "",
"email": ""
},
"asset": {
"lic": [
"NVY",
"FDA",
"Cardiovascular",
"Expedited Review",
"Unknown",
"GMP Exempt",
"Life Sustain Support",
"Implant",
"PMA",
"Class 3"
],
"price": {
"eow": {
"amount": 0,
"unit": "USD"
},
"cost": {
"amount": 0,
"unit": "USD"
},
"market": {
"amount": 0,
"unit": "USD"
}
},
"type": 0,
"stat": 3,
"market": "",
"tech": ""
},
"tag": [
"Cardiovascular",
"FDA",
"Unknown",
"Medical Device",
"Life Sustain Support",
"Implant",
"PMA",
"Class 3"
],
"logo": "https://buttondata.oss-cn-shanghai.aliyuncs.com/user.png"
}
{
"_perm": [],
"_etag": "e3728924fe527ab3932bdc7460a38644ed93916b",
"_id": "5c67f0c00f69d50010cb064d",
"nick": "",
"intro": "",
"type": 8,
"_auth": {
"mac": "",
"wechat": "",
"linkedin": "",
"pwd": ""
},
"_created": "Wed, 10 Aug 2016 00:00:00 GMT",
"ref": "NCT02878382",
"_deleted": false,
"_links": {
"self": {
"title": "Asset",
"href": "asset/5c67f0c00f69d50010cb064d"
}
},
"_updated": "Wed, 03 May 2017 00:00:00 GMT",
"addr": {
"country": "",
"city": "",
"zip": "",
"state": "",
"line1": "",
"line2": ""
},
"abs": "In topical photodynamic therapy (PDT) for non-melanoma skin cancers, a photosensitizing\n prodrug, 5-aminolaevulinic acid (ALA) or its methylated ester, methyl aminolevulinate (MAL),\n is converted to the endogenous photosensitizer protoporphyrinIX (PpIX).\n\n Reduced response rates are observed in thicker skin lesions, which may be due to insufficient\n PpIX accumulation within the target tissue.\n\n To enhance PpIX production,several physical and chemical pretreatments have been suggested.\n One of the chemical substances proposed to stimulate PpIX production is vitamin D because of\n its ability of being a keratinocyte pro-differentiating hormone.\n\n Based on in vitro and in animal model studies, we propose to study the potential impact of\n patient vitamin D pre-treatment in AK response to MAL-PDT.",
"srcId": "000000000000000000000000",
"pref": [],
"name": "Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT",
"onepage": {
"bg": "",
"team": "",
"prod": "",
"high": ""
},
"contact": {
"meet": "",
"phone": "",
"website": "",
"email": ""
},
"asset": {
"lic": [],
"price": {
"eow": {
"amount": 0,
"unit": "USD"
},
"cost": {
"amount": 0,
"unit": "USD"
},
"market": {
"amount": 0,
"unit": "USD"
}
},
"type": 2,
"stat": 3,
"market": "",
"tech": "#\n\n##\n\nClinicalTrials.gov processed this data on January 28, 2019\n\n##\n\nLink to the current ClinicalTrials.gov record.\n\n##\n\nhttps://clinicaltrials.gov/show/NCT02878382\n\n#\n\n##\n\n08/2016\n\n##\n\nNCT02878382\n\n#\n\nPDT\n\n#\n\nEfficacy of Calcipotriol Assisted MAL-PDT Versus Conventional MAL-PDT for Actinic Keratosis: a Randomized and Controlled Study\n\n#\n\nUniversity of Sao Paulo\n\n#\n\n##\n\nYes\n\n#\n\nA randomized, controlled Split -scalp study with Calcipotriol Assisted MAL-PDT versus\n conventional MAL-PDT for actinic keratosis (AK) is proposed.\n\n Twenty patients ( male gender only) with symmetrically distributed multiple AK lesions on the\n scalp will be included. Patients must have at least five AKs per field to be eligible.\n\n After simple randomization, one half of the scalp will be treated with Calcipotriol ointment\n 50 mcg/g (Daivonex, Leo Pharma, Denmark) for 15 consecutive days.\n\n After this period, the entire scalp will be submitted to topical PDT with\n Methylaminolevulinate 16% (Metvix, Galderma France) under occlusion for 90 minutes and then,\n illuminated with a light source consisting of a Light Emitting Diode device (LED) at 635 nm (\n Aktilite - Photocure, Norway). The total light dose will be 37J/cm2.\n\n Immediately before and after illumination with LED, measurements of the fluorescence\n intensity will be taken in 3 isolated spots in both sides of the scalp with a spectroscopy\n deviceUSB 2000+ ( Ocean Optics ® - Dunedin, Fl, USA).\n\n AK lesions will be counted and mapped by a dermatologist not involved in the study before and\n after 3 months.\n\n All patients will be advised to apply sunscreens 50 + 3x/day for the following 7 days after\n the procedure.\n\n A 0-10 Visual Analogue Scale (VAS) will be used to measure the pain intensity during the\n illumination.\n\n Records will be taken after 90 days and compared between sides: side effects, AK lesion\n response and pain level intensity.\n\n#\n\nOctober 2016\n\n#\n\n##\n\nActual\n\n##\n\nApril 2017\n\n#\n\n##\n\nActual\n\n##\n\nJanuary 2017\n\n#\n\nNo\n\n#\n\n##\n\nRandomized\n\n##\n\nParallel Assignment\n\n##\n\nTreatment\n\n##\n\nSingle (Outcomes Assessor)\n\n#\n\n##\n\nActinic keratosis response to treatment - lesion base count. Lesions will be mapped and counted before and after the treatment.\n\n##\n\nChange from baseline and 90 days after the PDT\n\n##\n\nTo compare the efficacy of topical PDT alone versus Calcipotriol assisted PDT for AKs on the scalp.\n\n#\n\n##\n\nPain level\n\n##\n\nbaseline\n\n##\n\nMeasurement of pain during LED illumination and comparison between the sides\n\n#\n\n##\n\nFluorescence intensity of PPIX\n\n##\n\nChange from baseline and 10 minutes after illumination\n\n##\n\nMeasurement of PPIX fluorescence on both sides of the scalp before and immediately after LED illumination\n\n#\n\n2\n\n#\n\n##\n\nActual\n\n##\n\n20\n\n#\n\nActinic Keratosis\n\n#\n\n##\n\nConventional MAL-PDT\n\n##\n\nOther\n\n##\n\nConventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.\n\n##\n\nCalcipotriol assisted MAL-PDT\n\n##\n\nOther\n\n##\n\nCalcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT\n\n#\n\n##\n\nOther\n\n##\n\nConventional MAL-PDT\n\n##\n\nCurettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose\n\n##\n\nConventional MAL-PDT\n\n##\n\nOther\n\n##\n\nCalcipotriol assisted MAL-PDT\n\n##\n\nCalcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose\n\n##\n\nCalcipotriol assisted MAL-PDT\n\n#\n\n##\n\nInclusion Criteria:\n\n - male gender\n\n - at least five AKs per field\n\n Exclusion Criteria:\n\n - history of photosensitivity related disorders\n\n - active infectious disease,\n\n - immunosuppression\n\n - laser or any cosmetic treatment in the previous 6 months\n\n - other topical agents in the treatment area such as retinoids, 5-fluorouracil,imiquimod\n or diclofenac sodium in the previous 3 months\n\n - allergy to MAL or excipients of the cream\n\n - poor patient compliance.\n\n##\n\nMale\n\n##\n\n50 Years\n\n##\n\n70 Years\n\n##\n\nAccepts Healthy Volunteers\n\n#\n\n##\n\n###\n\nUniversidade de Sao Paulo\n\n###\n\n####\n\nSao Paulo\n\n####\n\nSP\n\n####\n\n04543120\n\n####\n\nBrazil\n\n##\n\n###\n\nHospital Das Clinicas Universidade Sao Paulo\n\n###\n\n####\n\nSao Paulo\n\n####\n\nSP\n\n####\n\nBrazil\n\n#\n\n##\n\nBrazil\n\n#\n\nMay 2017\n\n#\n\nAugust 10, 2016\n\n#\n\nAugust 24, 2016\n\n#\n\n##\n\nEstimate\n\n##\n\nAugust 25, 2016\n\n#\n\nMay 3, 2017\n\n#\n\nMay 3, 2017\n\n#\n\n##\n\nActual\n\n##\n\nMay 8, 2017\n\n#\n\n##\n\nPrincipal Investigator\n\n##\n\nUniversity of Sao Paulo\n\n##\n\nLuis Antonio Torezan\n\n##\n\nAssistant Professor of Dermatology\n\n#\n\n##\n\nYes"
},
"tag": [
"Interventional",
"Completed",
"N/A",
"PDT",
"skin cancer",
"calcipotriol",
"Other",
"Other",
"Keratosis",
"Keratosis, Actinic",
"Calcipotriene",
"Calcitriol"
],
"logo": "https://buttondata.oss-cn-shanghai.aliyuncs.com/user.png"
}
{
"_perm": [],
"_etag": "b057c9a2e39d8a2ebb623c1d34b01b6fd0e2ac19",
"_id": "5c6faa2a0f69d50010c5df92",
"nick": "",
"type": 2,
"intro": "",
"entr": {
"bp": "",
"fin": "",
"demand": {
"amount": {
"amount": 0,
"unit": "USD"
},
"val": {
"amount": 0,
"unit": "USD"
},
"due": "Thu, 01 Jan 1970 00:00:00 GMT",
"share": 0,
"stage": 11
},
"grant": "",
"market": "",
"tech": ""
},
"_auth": {
"mac": "",
"wechat": "",
"linkedin": "",
"pwd": ""
},
"_created": "Fri, 22 Feb 2019 06:52:35 GMT",
"ref": "https://pharmalicensing.com/app/zcompanyprofile/445",
"_updated": "Fri, 22 Feb 2019 06:52:35 GMT",
"_links": {
"self": {
"title": "Entrepreneur",
"href": "entrepreneur/5c6faa2a0f69d50010c5df92"
}
},
"_deleted": false,
"addr": {
"country": "United States",
"city": "Unknown",
"zip": "",
"line1": "",
"state": "",
"line2": ""
},
"abs": "Wistar Institute",
"srcId": "000000000000000000000000",
"pref": [],
"name": "Wistar Institute",
"onepage": {
"bg": "",
"team": "",
"prod": "",
"high": ""
},
"contact": {
"email": "",
"website": "",
"phone": "",
"meet": ""
},
"tag": [
"esP rnuvIait"
],
"logo": "https://buttondata.oss-cn-shanghai.aliyuncs.com/user.png"
}